Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO -- Ignore unavailable to you. Want to Upgrade?

To: Extra Pale who wrote (413)	1/3/2002 9:16:37 AM
From: Extra Pale	Respond to of 438

p53 article (thanks, Savant) msnbc.com

To: Extra Pale who wrote (413)	1/5/2002 9:58:08 PM
From: jeffbas	Read Replies (1) \| Respond to of 438

I do not trust GENZ either. They have huge conflicts of interest in managing these companies. By the way, GZSP was another example of the holders getting royally screwed by GENZ with the Biomatrix deal. On the other hand, the resources that GZMO implicitly and explicitly has available from GENZ far exceed those of any other similar biotech company. However, despite having held this for years since $2+, except for selling some in early 2000, I am now a lot less enchanted with the company. The lack of the promised antigen discovery deal is one thing. My growing (and not particularly well-informed) view that this is a research lab operation without much commitment to commercial success is another.